"Mycophenolic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.
| Descriptor ID |
D009173
|
| MeSH Number(s) |
D02.241.081.193.678 D10.251.618
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mycophenolic Acid".
Below are MeSH descriptors whose meaning is more specific than "Mycophenolic Acid".
This graph shows the total number of publications written about "Mycophenolic Acid" by people in this website by year, and whether "Mycophenolic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 6 | 0 | 6 |
| 1999 | 3 | 2 | 5 |
| 2000 | 0 | 1 | 1 |
| 2001 | 4 | 0 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 4 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 2 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 3 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mycophenolic Acid" by people in Profiles.
-
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
-
Immunosuppression in Uterus Transplantation: Experience From the Dallas Uterus Transplant Study. Transplantation. 2023 03 01; 107(3):729-736.
-
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res. 2023 Jan 09; 24(1):6.
-
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation. Prog Transplant. 2022 12; 32(4):363-369.
-
Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus. 2022 Oct; 31(12):1508-1515.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus. 2020 May; 29(6):569-577.
-
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
-
Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103.